Cargando…

Tumor fitness, immune exhaustion and clinical outcomes: impact of immune checkpoint inhibitors

Recently proposed tumor fitness measures, based on profiling neoepitopes for reactive viral epitope similarity, have been proposed to predict response to immune checkpoint inhibitors in melanoma and small-cell lung cancer. Here we applied these checkpoint based fitness measures to the matched checkp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bubie, Adrian, Gonzalez-Kozlova, Edgar, Akers, Nicholas, Villanueva, Augusto, Losic, Bojan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081289/ https://www.ncbi.nlm.nih.gov/pubmed/32193450 http://dx.doi.org/10.1038/s41598-020-61992-2

Ejemplares similares

Landscape of oncoviral genotype and co-infection via human papilloma and hepatitis B viral tumor in situ profiling
por: Bubie, Adrian, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors and the Heart
por: Mocan-Hognogi, Diana Larisa, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors for the Therapy of Thymoma
por: Quilez, Alicia, et al.
Publicado: (2020)

Inhibitory immune checkpoints cause exhaustion of viral immunity in coronary artery disease
Publicado: (2022)

STAR Chimeric Post for rapid detection of circular RNA and fusion transcripts
por: Akers, Nicholas K, et al.
Publicado: (2018)

Future of immune checkpoint inhibitors: focus on tumor immune microenvironment
por: Jia, Yunlong, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor Therapy in Neuroendocrine Tumors
por: Gubbi, Sriram, et al.
Publicado: (2022)

Immune Checkpoint Molecules and Glucose Metabolism in HIV-Induced T Cell Exhaustion
por: Chan, Yee Teng, et al.
Publicado: (2022)

The CD73 immune checkpoint promotes tumor cell metabolic fitness
por: Allard, David, et al.
Publicado: (2023)

Immune checkpoint inhibitors
por: Hui, Enfu
Publicado: (2019)

Immune checkpoint inhibitors
por: Kroemer, Guido, et al.
Publicado: (2021)

Immune checkpoint inhibitors in cancer therapy
por: Webb, Eika S., et al.
Publicado: (2018)

Hypokalemic Paralysis Secondary to Immune Checkpoint Inhibitor Therapy
por: Balakrishna, Pragathi, et al.
Publicado: (2017)

Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma
por: Baba, Yoshifumi, et al.
Publicado: (2020)

Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
por: Das, Satya, et al.
Publicado: (2019)

Antibiotic therapy and outcome from immune-checkpoint inhibitors
por: Pinato, David J., et al.
Publicado: (2019)

Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity
por: Farina, Antonio, et al.
Publicado: (2023)

Cardiotoxicity of immune checkpoint inhibitors
por: Varricchi, Gilda, et al.
Publicado: (2017)

Cardiotoxicity of Immune Checkpoint Inhibitors
por: Patel, Rushin P., et al.
Publicado: (2021)

Immune Checkpoint Inhibitors and Neurotoxicity
por: Zhao, Zhiyi, et al.
Publicado: (2021)

The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors
por: Meyers, Daniel E., et al.
Publicado: (2019)

The Current Landscape of Immune Checkpoint Inhibitor Immunotherapy for Primary and Metastatic Brain Tumors
por: Alimonti, Paolo, et al.
Publicado: (2023)

Characterizing tumor shrinkage as a measure of clinical benefit for immune checkpoint inhibitors
por: Kelleher, Thomas, et al.
Publicado: (2021)

The tumor microbiome as a predictor of outcomes in patients with metastatic melanoma treated with immune checkpoint inhibitors
por: Wheeler, Caroline E., et al.
Publicado: (2023)

Expression of immune checkpoints and T cell exhaustion markers in early and advanced stages of colorectal cancer
por: Saleh, Reem, et al.
Publicado: (2020)

Insufficiency of compound immune checkpoint blockade to overcome engineered T cell exhaustion in pancreatic cancer
por: Stromnes, Ingunn M, et al.
Publicado: (2022)

Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity
por: Seliger, Barbara
Publicado: (2019)

Hyperthermia Targeting the Tumor Microenvironment Facilitates Immune Checkpoint Inhibitors
por: Li, Zihui, et al.
Publicado: (2020)

Host response to immune checkpoint inhibitors contributes to tumor aggressiveness
por: Khononov, Irina, et al.
Publicado: (2021)

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
por: Naimi, Adel, et al.
Publicado: (2022)

Immune checkpoint inhibitors in Wilms' tumor and Neuroblastoma: What now?
por: Valind, Anders, et al.
Publicado: (2021)

What is the optimal duration of immune checkpoint inhibitors in malignant tumors?
por: Yin, Jiaxin, et al.
Publicado: (2022)

Increasing cure rates of solid tumors by immune checkpoint inhibitors
por: Ma, Weijie, et al.
Publicado: (2023)

Immune checkpoint inhibitors unleash pathogenic immune responses against the microbiota
por: Hu, Zishuo Ian, et al.
Publicado: (2022)

Emerging Immune-Monitoring System for Immune Checkpoint Inhibitors
por: Hamada, Kazuyuki, et al.
Publicado: (2022)

The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma
por: Meti, Nicholas, et al.
Publicado: (2018)

The Impact of Tregs on the Anticancer Immunity and the Efficacy of Immune Checkpoint Inhibitor Therapies
por: González-Navajas, Jose M., et al.
Publicado: (2021)

Immune checkpoint inhibitors, endocrine adverse events, and outcomes of melanoma
por: Karhapää, Hanna, et al.
Publicado: (2022)

Targeting Cancer Metabolism to Improve Outcomes with Immune Checkpoint Inhibitors
por: Fatima, Zainab, et al.
Publicado: (2023)

Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies
por: Hernandez, Carlos, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_f7fe3057ahmsuq1f1t4lrv53eq